

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

X



Memorial Sloan Kettering  
Cancer Center

[About Us](#)  
[Sloan Kettering Institute](#)

[Research](#)

MOLECULAR BIOLOGY PROGRAM


## The Andrew Koff Lab

[Education & Training](#)

## Research

[News & Events](#)

[Open Positions](#)



Andrew Koff, PhD

---

My laboratory has combined biochemical, molecular, cellular, and genetic approaches to investigate the roles of CDK inhibitors in differentiation, development, and cancer biology. An additional major focus of the laboratory is directed towards understanding how these gene products are regulated to accomplish these roles.

[View Lab Overview \(<https://www.mskcc.org/research/ski/labs/andrew-koff/overview>\)](https://www.mskcc.org/research/ski/labs/andrew-koff/overview)

## Research Projects

- [The Lab of Cell Cycle Regulation](#)
- [Clinical Implications of SAGA](#)



## Publications Highlights

Kovatcheva M, Liu DD, Dickson MA, Klein ME, O'Connor R, Wilder FO, Socci ND, Tap WD, Schwartz GK, Singer S, Crago AM, and Koff A. MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. *Oncotarget* 10: 8226-43, 2015

---

Abbas Manji G, Singer S, Koff A, and Schwartz GK. Application of molecular biology to individualize therapy for patients with liposarcoma. *Am Soc Clin Oncol Educ Book*. 2015:213-8

---

Dickson MA, Schwartz GK, Keohan ML, D'Angelo SP, Gounder MM, Chi P, Antonescu CR,

Landa J, Qin LX, Crago AM, Singer S, Koff A, and Tap WD. Progression free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: A phase 2 clinical trial. *JAMA Oncol* 2: 937-40, 2016.

---


Kovatcheva M, Liao W, Klein ME, Robine N, Geiger H, Crago AM, Dickson MA, Tap WD, Singer S, and Koff A. ATRX is a novel regulator of therapy induced senescence in human cells. *Nat. Comms.* 8:386, 2017

---

Kovatcheva M, Klein ME, Tap WD, and Koff A. Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors. *Mol Cell Oncol* 5:e1384882, 2018

[View All Publications](#)

## People



## Andrew Koff, PhD

- Molecular biologist Andrew Koff is interested in identifying the genes and molecular mechanisms by which cells make decisions regarding their proliferative capacity after they exit from the cell cycle during therapy induced senescence and during normal development.

 [a-koff@ski.mskcc.org](mailto:a-koff@ski.mskcc.org)

Email Address

 [212-639-2354](tel:212-639-2354)

Office Phone

## Members

 Tarsha Barton

 Marimar Benitez De La Vega

## Lab Affiliations

## Open Positions

To learn more about available postdoctoral opportunities, please visit our [Career Center](#)

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit [Resources for Postdocs](#)

## Get in Touch

 [a-koff@ski.mskcc.org](mailto:a-koff@ski.mskcc.org)



Juliana I. Delgado



Caroline Gleason  
Medical Associate, The  
Scienomics Group, New York,  
NY

Lab Head Email

📞 [212-639-2354](tel:212-639-2354)

Office Phone

📞 [212-639-2355 / 2356](tel:212-639-2355 / 2356)

Lab Phone

📞 [646-422-2062](tel:646-422-2062)


Lab Fax



Mary E. Klein Dooley  
Project Manager at University of  
Pennsylvania, Philadelphia, PA



Marta Kovatcheva  
Principal Investigator, Cllc  
Plasticity and Agining, IFOM



Henry Somerby  
management is needed.

## Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

These activities outside of MSK further our mission, provide productive collaborations, and

promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI

Andrew Koff discloses the following relationships and financial interests:

- Atropos Therapeutics, Inc.  
Equity; Intellectual Property Rights; Professional Services and Activities (Uncompensated)

- Concarlo Therapeutics, Inc.  
Professional Services and Activities
- Eli Lilly and Company  
Professional Services and Activities (Uncompensated)
- Novartis Institutes for BioMedical Research, Inc.  
Professional Services and Activities (Uncompensated)

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org) .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

© 2026 Memorial Sloan Kettering Cancer Center